DSGN Stock Overview
Design Therapeutics, Inc. a preclinical-stage biopharmaceutical company, engages in the development of therapies for the treatment of genetic diseases caused by nucleotide repeat expansions.
Notes are coming soon
Design Therapeutics, Inc. Competitors
Price History & Performance
|Historical stock prices|
|Current Share Price||US$8.27|
|52 Week High||US$26.30|
|52 Week Low||US$6.94|
|1 Month Change||-19.71%|
|3 Month Change||-48.63%|
|1 Year Change||-33.89%|
|3 Year Change||n/a|
|5 Year Change||n/a|
|Change since IPO||-80.07%|
Recent News & Updates
Companies Like Design Therapeutics (NASDAQ:DSGN) Are In A Position To Invest In GrowthOct 25
We're Not Very Worried About Design Therapeutics' (NASDAQ:DSGN) Cash Burn RateJul 02
Companies Like Design Therapeutics (NASDAQ:DSGN) Are In A Position To Invest In GrowthMar 18
Companies Like Design Therapeutics (NASDAQ:DSGN) Are In A Position To Invest In GrowthDec 03
Here's Why We're Not Too Worried About Design Therapeutics' (NASDAQ:DSGN) Cash Burn SituationAug 18
|DSGN||US Biotechs||US Market|
Return vs Industry: DSGN underperformed the US Biotechs industry which returned 7.1% over the past year.
Return vs Market: DSGN underperformed the US Market which returned -9.7% over the past year.
|DSGN Average Weekly Movement||14.2%|
|Biotechs Industry Average Movement||12.2%|
|Market Average Movement||6.9%|
|10% most volatile stocks in US Market||17.3%|
|10% least volatile stocks in US Market||2.8%|
Stable Share Price: DSGN is more volatile than 75% of US stocks over the past 3 months, typically moving +/- 14% a week.
Volatility Over Time: DSGN's weekly volatility (14%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company
Design Therapeutics, Inc. a preclinical-stage biopharmaceutical company, engages in the development of therapies for the treatment of genetic diseases caused by nucleotide repeat expansions. The company’s portfolio of products comprises Friedreich Ataxia, a monogenic, autosomal recessive, progressive multi-system disease that affects organ systems dependent on mitochondrial function, eventually leading to neurological, cardiac, and metabolic dysfunction; and Myotonic Dystrophy Type-1 (DM1), a dominantly-inherited, monogenic progressive neuromuscular disease affecting skeletal muscle, heart, brain, and other organs. It is also developing GeneTAC product candidate portfolio for the treatment of other nucleotide repeat expansion-driven monogenic diseases, such as Fragile X syndrome, spinocerebellar ataxias, amyotrophic lateral sclerosis, frontotemporal dementia, Huntington disease, and spinobulbar muscular atrophy.
Design Therapeutics, Inc. Fundamentals Summary
|DSGN fundamental statistics|
Is DSGN overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|DSGN income statement (TTM)|
|Cost of Revenue||US$27.07m|
Last Reported Earnings
Sep 30, 2022
Next Earnings Date
|Earnings per share (EPS)||-1.02|
|Net Profit Margin||0.00%|
How did DSGN perform over the long term?See historical performance and comparison